Patents by Inventor Anne Worsaae

Anne Worsaae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-AXL antibodies and compositions
    Patent number: 11807688
    Abstract: This invention relates to anti-AXL antibodies and methods of using them in treating diseases and conditions related to AXL activity, e.g., cancer.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: November 7, 2023
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Torben Gjetting, Trine Lindsted, Anton Willer, Anne Worsaae, Maria Carlsen Melander, Janus Schou Jakobsen, Randi Westh Hansen
  • ANTI-NKG2A ANTIBODIES AND COMPOSITIONS
    Publication number: 20220389100
    Abstract: This invention relates to anti-NKG2A antibodies and methods of using them in enhancing immunity in a patient in need thereof and in treating cancer.
    Type: Application
    Filed: May 31, 2022
    Publication date: December 8, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Randi Westh Hansen, Franziska Katharina Uhlenbrock, Nikolaj Dietrich, Anne Worsaae, Michael Monrad Grandal
  • Anti-AXL Antibodies and Compositions
    Publication number: 20210269532
    Abstract: This invention relates to anti-AXL antibodies and methods of using them in treating diseases and conditions related to AXL activity, e.g., cancer.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 2, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Torben GJETTING, Trine LINDSTED, Anton WILLER, Anne WORSAAE, Maria Carlsen MELANDER, Janus Schou JAKOBSEN, Randi Westh HANSEN
  • IL-21 derivatives and variants
    Patent number: 8450459
    Abstract: The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: May 28, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Bernd Peschke, Christine Bruun Schiødt, Helle Wöldike, Florencio Zaragoza Dörwald, Anne Worsaae
  • IL-21 Derivatives and Variants
    Publication number: 20090253864
    Abstract: The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules.
    Type: Application
    Filed: August 12, 2008
    Publication date: October 8, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Bernd Peschke, Christine Bruun Schiodt, Helle Woldike, Florencio Zaragoza Dorwald, Anne Worsaae
  • IL-21 Derivatives and variants
    Publication number: 20060228331
    Abstract: The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules.
    Type: Application
    Filed: April 10, 2006
    Publication date: October 12, 2006
    Applicant: Novo Nordisk A/S
    Inventors: Bernd Peschke, Christine Schiodt, Helle Woldike, Florencio Dorwald, Anne Worsaae
  • Prevention of diabetes
    Publication number: 20010041669
    Abstract: Insulins and insulin analogues which are substantially devoid of hypoglycaemic effect can be used for preventing or delaying the onset of type 1 diabetes or for amelioration of an early stage thereof in a mammal at risk of developing said disease.
    Type: Application
    Filed: June 1, 2001
    Publication date: November 15, 2001
    Inventors: Thomas Dyrberg, Anne Worsaae
  • Prevention of diabetes
    Publication number: 20010021696
    Abstract: Insulins and insulin analogues which are substantially devoid of hypoglycaemic effect can be used for preventing or delaying the onset of type 1 diabetes or for amelioration of an early stage thereof in a mammal at risk of developing said disease.
    Type: Application
    Filed: May 2, 2001
    Publication date: September 13, 2001
    Inventors: Thomas Dyrberg, Anne Worsaae
  • Treatment of type 1 diabetes
    Patent number: 6274549
    Abstract: Insulin analogues which are substantially devoid of hypoglycemic effect can be used for treating of delaying the onset of type 1 diabetes or ameliorating of an early stage thereof in a mammal at risk of developing diabetes.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: August 14, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Dyrberg, Anne Worsaae